Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17963859 | 0.91 | P2RX3 (0.34) | P2RX3GPR119JAK1PIK3CDALDH1A1 | |
| SCHEMBL19759342 | 0.90 | P2RX3 (0.33) | P2RX3GPR119JAK1PIK3CDALDH1A1 | |
| SCHEMBL17628831 | 0.89 | GPR119 (0.34) | P2RX3GPR119JAK1PIK3CDALDH1A1 | |
| SCHEMBL17628916 | 0.84 | GPR119 (0.31) | GPR119 | |
| SCHEMBL17495396 | 0.82 | PDK4 (0.43) | GPR119BTKGRM5 | |
| SCHEMBL30213802 | 0.82 | PDK4 (0.43) | GPR119BTKGRM5 | |
| SCHEMBL17628927 | 0.79 | GPR119 (0.32) | P2RX3GPR119PIK3CD | |
| SCHEMBL17963825 | 0.78 | JAK1 (0.33) | JAK1ALDH1A1 | |
| SCHEMBL17628816 | 0.76 | ALDH1A1 (0.30) | ALDH1A1MAPTLMNA | |
| SCHEMBL17629003 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426135-B2 | Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190150401-A1 | Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | PFIZER INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9920054-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170233390-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3197882-A1 | METHYL-AND TRIFLUOROMETHYL-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9670201-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2016046755-A1 | METHYL-AND TRIFLUOROMETHYL-SUBSTITUTED PYRROLOPYRIDINE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160090381-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER (US) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | RORC, RORB, RORA | P2RX3 231/4885GPR119 578/4885JAK1 891/4885 |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | P2RX3 342/4885GPR119 493/4885JAK1 830/4885 |
| US-20170233390-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | P2RX3 342/4885GPR119 493/4885JAK1 830/4885 |
| US-20160090381-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | P2RX3 342/4885GPR119 493/4885JAK1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.